$ACRV

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.

Acrivon Therapeutics acquired JAK1 inhibitor ACR-525 and a PKCθ program, focusing on immunology and inflammation. ACR-525 is Phase 2-ready for eosinophilic esophagitis, with potential in inflammatory bowel disease. The deal involved cash payment with no future obligations. Acrivon sees ACR-525 as a best-in-class JAK1 inhibitor.

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB Asset acquisition establishes immunology and inflammation (I&I) as a strategic pilla

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

Acrivon Therapeutics (ACRV) announced progress in its oral CDK11 inhibitor, ACR-7280, advancing it to IND-enabling studies. The company aims to file an IND in the first half of 2027, with an initial focus on acute myeloid leukemia (AML) after demonstrating complete tumor regression in xenograft models.

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 P

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 acrv-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Acrivon Therapeutics, Inc. Amended and Restated 2022 Equity Incentive Plan Adopted by the Board of Directors: May 20, 2026 Approved by the Stockholders: June 17, 2026 1. General. (a) Successor to and Continuation of Prior Pla

Acrivon Therapeutics, Inc.'s Chief Operating Officer, Eric Devroe, had 613 shares of Common Stock withheld on May 14, 2026, to cover tax obligations related to restricted stock unit vesting. The shares were valued at $1.92 each for this administrative tax-withholding disposition, which is not an open-market sale. Following this transaction, Devroe directly holds 73,972 Common Stock shares, maintaining his equity position after satisfying the required tax liability.

This article analyzes the historical performance of investing $1,000 in Acrivon Therapeutics, Inc. (ACRV) over one, five, and ten years, showing significant losses and underperformance compared to the S&P 500. It also provides a detailed overview of Acrivon Therapeutics, explaining its proprietary Generative Phosphoproteomics AP3 platform, its lead clinical candidates ACR-368 and ACR-2316, and its preclinical pipeline. The company is a clinical-stage biopharmaceutical firm focused on precision oncology using AI-driven drug discovery and companion diagnostics.

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development